Shares of Regenxbio (RGNX) were surging premarket Monday after the biotechnology company reported new, positive data from the phase I/II portion of a study evaluating RGX-202 gene therapy for Duchenne muscular dystrophy.
The company also said the gene therapy has advanced to a pivotal stage with a first patient dosed. RGX-202 will now be evaluated in the pivotal trial in about 30 patients aged 1 and older, according to Regenxbio.
Regenxbio also said it is "quickly advancing" the gene therapy toward a biologics license application filing in 2026.
Price: 9.19, Change: +0.40, Percent Change: +4.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.